跳转至内容
Merck
CN

SML3739

AZ Dyrk1B 33

≥98% (HPLC)

别名:

3-(2-Methyl-4-pyrimidinyl)-1-(phenylmethyl)-1H-pyrrolo[2,3-c]pyridine, AZ-Dyrk1B-33

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C19H16N4
化学文摘社编号:
分子量:
300.36
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Quality Level

Biochem/physiol Actions

Potent and selective Dyrk1B kinase inhibitor that increased the number of incretin-expressing cells in diabetic mice.
AZ Dyrk1B 33 is a potent and selective Dyrk1B kinase (dual-specificity tyrosine phosphorylation-regulated kinase 1B) inhibitor. AZ Dyrk1B 33 potently increases the numbers of neurogenin 3-expressing enteroendocrine progenitors, Gip-expressing K-cells, and Glp-1-expressing L-cells in zebrafish and diabetic mice. It decreases glucose levels in both larval and juvenile zebrafish.

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesis
Journal of medicinal chemistry, 58(6), 2834-2844 (2015)
Developing DYRK inhibitors derived from the meridianins as a means of increasing levels of NFAT in the nucleus
Bioorganic & Medicinal Chemistry Letters, 27(11), 2617-2621 (2017)
Lianhe Chu et al.
Cell chemical biology, 29(9), 1368-1380 (2022-08-24)
Analogs of the incretin hormones Gip and Glp-1 are used to treat type 2 diabetes and obesity. Findings in experimental models suggest that manipulating several hormones simultaneously may be more effective. To identify small molecules that increase the number of

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持